Dr. Glaucomflecken Explains: Enfortumab Vedotin and Pembrolizumab in Bladder Cancer (KEYNOTE-905) @NEJMgroup
Dr. Glaucomflecken Explains: Enfortumab Vedotin and Pembrolizumab in Bladder Cancer (KEYNOTE-905) @NEJMgroup
Uploaded May 2026 | Updated September 2026, 2 weeks ago
The latest video in our partnership with @DGlaucomflecken explains the KEYNOTE-905 trial that assessed the efficacy and safety of perioperative enfortumab vedotin plus pembrolizumab and surgery in cisplatin-ineligible patients with muscle-invasive bladder cancer.

View the Original Article for free: https://nej.md/DrG40

#oncology #urology #NEJM
Dr. Glaucomflecken Explains: Enfortumab Vedotin and Pembrolizumab in Bladder Cancer (KEYNOTE-905)OpenAIโ€™s Karan Singal on HealthBench and the Future of Medical AIIntention to Treat: The Race Equation (Teaser)Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk (SINGLE-AF)NEJM Outbreaks Updates โ€” Andes HantavirusNEJM This Week โ€” August 13, 2026Dr. Glaucomflecken Explains: Transdermal Estradiol in Prostate CancerBiDil โ€” The Story of the Black PillImage Challenge โ€” May 7, 2026High-Reliability Organizing: Refreshing a Proven Framework for Modern Health Care ChallengesClinical Practice: Prevention and Treatment of Peanut AllergyDr. Glaucomflecken Explains: Rituximab versus Ocrelizumab in Relapsing Multiple Sclerosis
NEJM Group |

Dr. Glaucomflecken Explains: Enfortumab Vedotin and Pembrolizumab in Bladder Cancer (KEYNOTE-905)

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER